Vyndaqel

This is a summary of the European public assessment report (EPAR) for Vyndaqel. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Vyndaqel. This product originally had an [orphan designation for familial amyloid polyneuropathy](/en/medicines/human/orphan-designations/eu-3-06-401), granted on 28 August 2006. This designation was withdrawn from the Community register of orphan medicinal products in November 2021 at the end of the 10-year period of market exclusivity.